Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vortosiran vs Apixaban in Non-valvular Atrial Fibrillation
NCT07870889Phase 2Not yet recruiting
- Sponsor
- Ribocure Pharmaceuticals AB
- Start
- Oct 2026
- Primary completion
- Jul 2028
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of vortosiran in nonvalvular atrial fibrillation (NVAF) (3 arms), sponsored by Ribocure Pharmaceuticals AB. Primary endpoint: Primary Objective (Safety and Pharmacodynamics) at 16 weeks. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
vortosiran
03
Conditions
nonvalvular atrial fibrillation (NVAF)
Beyond the preview
Go deeper on NCT07870889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07870889.